SIRT1 and adiponectin together operate to adjust the gluco-lipidic profile, to mediate the white adipose tissue browning [44] and, most importantly, to antagonize insulin resistance, fatty liver diseases and inflammatory responses. Here, ADIPOQ is linked to fatty liver disease.